


Accepted Manuscript

More Than a Decade Follow-up in Severe or Difficult-to-Treat Asthma: TENOR II

Bradley E. Chipps, MD, Tmirah Haselkorn, PhD, Brandee Paknis, PharmD, Benjamin Ortiz, MD, Eugene R. Bleecker, MD, Farid Kianifard, PhD, Aimee J. Foreman, MA, Stanley J. Szeffler, MD, Robert S. Zeiger, MD, PhD



PII: S0091-6749(17)31270-8

DOI: [10.1016/j.jaci.2017.07.014](https://doi.org/10.1016/j.jaci.2017.07.014)

Reference: YMAI 12951

To appear in: *Journal of Allergy and Clinical Immunology*

Received Date: 14 September 2016

Revised Date: 10 July 2017

Accepted Date: 19 July 2017

Please cite this article as: Chipps BE, Haselkorn T, Paknis B, Ortiz B, Bleecker ER, Kianifard F, Foreman AJ, Szeffler SJ, Zeiger RS, for the TENOR Study Group, More Than a Decade Follow-up in Severe or Difficult-to-Treat Asthma: TENOR II, *Journal of Allergy and Clinical Immunology* (2017), doi: 10.1016/j.jaci.2017.07.014.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **More Than a Decade Follow-up in Severe or Difficult-to-Treat Asthma:**
2 **TENOR II**

3 Bradley E Chipps, MD^a; Tmirah Haselkorn, PhD^b; Brandee Paknis, PharmD^c; Benjamin Ortiz, MD^c;
4 Eugene R Bleecker, MD^d, Farid Kianifard, PhD^c; Aimee J Foreman, MA^e; Stanley J Szeffler, MD^f;
5 Robert S Zeiger, MD, PhD^g for the TENOR Study Group

6

7 ^aCapital Allergy and Respiratory Disease Center, Sacramento, California; ^bEpiMetrix, Inc., Los Altos,
8 California; ^cNovartis Pharmaceuticals Corp., East Hanover, New Jersey; ^dWake Forest University,
9 Winston-Salem, North Carolina; ^eICON Plc, San Francisco, California; ^fChildren's Hospital,
10 Colorado, Aurora, Colorado; ^gDepartment of Allergy, Kaiser Permanente Southern California, San
11 Diego, California

12

13 **Corresponding author:** Bradley E. Chipps, MD, Capital Allergy and Respiratory Disease Center,
14 5609 J St, Suite C, Sacramento, CA 95819. Tel: (916) 453-1454; Fax: (916) 453-2786 Email:
15 bchipps@capitalallergy.com

16

17 **Funding source:** The TENOR II study was sponsored by Genentech, Inc. and Novartis
18 Pharmaceuticals Corp. Novartis Pharmaceuticals Corp also provided writing support for the
19 preparation of this article.

20

21 **Disclosures:** Genentech Inc and Novartis Pharmaceuticals Corp designed and sponsored the study
22 and analysed the data. The sponsors were involved in the design of the study, and in collection,
23 analysis and interpretation of the data. Three of the authors (BP, BO, KF) are employees of the above
24 companies; beyond this involvement, the sponsors had no involvement in the review or writing of the
25 manuscript. The decision as to where to submit the manuscript was made by the authors with no
26 employment connection to the sponsors.

27

Download English Version:

<https://daneshyari.com/en/article/8713163>

Download Persian Version:

<https://daneshyari.com/article/8713163>

[Daneshyari.com](https://daneshyari.com)